FOREX 3 minutes to read

AbbVie puckers up for Botox-maker

Summary:  Big pharma is hitting the headlines today after AbbVie Inc (ABBV: NYSE) puckered up, then ponied up $63.0 billion in cash and stock to acquire Botox-maker Allergan (AGN: NYSE).


Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each AGN share, making the deal worth $188.24/per AGN share. The combined companies are projected to generate $19.0 billion in operating cash flow with expected annual synergies and cost savings of $2.0 billion in year three. Closing is planned for early 2020, subject to regulatory and AGN shareholder approvals. AGN jumped 30%, and ABBV lost 10.17% at the New York open.

The news wasn’t enough for Wall Street to extend the June rally. The three major indices were modestly lower as of 14:00 GMT but are still up over 4.0% for the month. Mixed US data, which included a slightly softer Case-Shiller Home Price Index. (Actual 2.5% vs forecast 2.6%) was ignored.

Traders that believe the stock market rally was because of the Fed’s dovish shift and the prospect of two rate cuts before the end of the year, would be wrong. President Trump tweeted the real reason for the gains: “Stock Market is heading for one of the best months (June) in the history of our Country. Thank you Mr. President!”

USDCAD drifted lower, probing support in the 1.3130-50 zone. Prices are under pressure due to the surge in crude oil prices and from broad US dollar weakness. A surprising jump in Canadian Wholesale Sales in April (actual 1.7% m/m vs forecast 0.2%) added to the negative sentiment. 

FX markets remain cautious do the ongoing US/Iran tensions and ahead of news from the next round of China/US trade talks. Fed Chair Powell is speaking at lunchtime in New York but isn’t expected to deviate from his post-FOMC press conference remarks.
Chart:USDCAD 30 minute. Source: Saxo Bank.
Disclaimer

Saxo Capital Markets (Australia) Pty Ltd prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Combined Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)